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Transcription, not synthesis, of interleukin.1 and tumor necrosis factor
by complement. Stimulation of interleukin-113 (IL-1/3) and tumor necro-
sis factor (TNFa) production was studied during in vitro hemodialysis
(HD) of whole blood using cuprammonium (Cup) or polysulfone (PS)
dialyzers. In the absence of LPS, circulation of whole blood for two
hours through Cup or PS dialyzers was not sufficient to induce
production of IL-l/3 or TNFc in peripheral blood mononuclear cells
(PBMC) during subsequent 24 hour culture. However, compared to
freshly isolated cells, post-HD PBMC were primed to produce more
IL-l/3 and TNFa when subsequently stimulated with LPS. Despite the
lack of spontaneous monokine synthesis after HD, we observed tran-
scription of mRNA coding for IL-lf3 and TNFa after two hours of
LPS-free HD. When compared to levels of mRNA induced by 5 ng/ml
LPS (100%), Cup induced 27 6% whereas PS did not induce
detectable transcription of IL-1f3. In the case of TNFs mRNA, Cup
induced 26 8% and PS 13 3%. Recombinant C5a induced mRNA
for IL-1f3 in PBMC without detectable IL-1/3 protein synthesis. We
conclude that transcription of mRNA for IL-I/i and TNFa during HD is
primarily caused by complement activation by Cup, but that LPS or
other factors are required for translation of IL-I p and TNFa mRNA
transcribed during HD.
Interleukin-l (IL-i) and tumor necrosis factor (TNFa) are
members of a family of monokines that are produced by a
variety of cell types, particularly monocytes and macrophages
[1, 2]. IL-I has been studied under the term endogenous
pyrogen for more than three decades [3]. It is now evident that
besides inducing fever, IL-I has numerous other biological
effects that are often indistinguishable from the signs observed
after microbial invasion and injury. They include T cell activa-
tion, hepatic acute phase protein synthesis and neutrophilia, as
well as hemodynamic shock and tissue damage. The two forms
of IL-I (s and 3) as well as TNFa are also part of a self-
augmenting network of inflammatory cytokines since they
stimulate their own and each other's production in vivo and in
vitro [4, 5]. Moreover, IL-i and TNFapotentiate their effects in
a synergistic manner, for example, in synthesis of prostaglan-
dins, the induction of hypotension and shock in rabbits, the
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induction of hepatic acute phase proteins and cytotoxicity
[6-8].
The induction of IL-i and TNFa from peripheral blood
mononuclear cells (PBMC) during hemodialysis (HD) may be
an important mechanism in the onset of acute and/or chronic
pathological changes associated with HD therapy [9—111. The
clinical relevance of IL-i in HD is supported by the observation
of elevated plasma levels of IL-i in HD patients. Moreover,
plasma IL-i activity increases during a single hemodialysis
session [12, 13] and the rise in plasma IL-i activity appears to
be dependent on the choice of the HD membrane [14].
There are at least three triggering events for monokine
induction during HD: 1) direct contact between PBMC and the
membrane; 2) bacterial contamination of the dialysate; and 3)
complement components activated by the membrane. Consid-
ering the first of these, LPS and its fragments are potent
inducers of IL-i production and can be found in dialysate used
in routine HD up to concentrations 1 ,000-fold or greater than
that required for the induction of IL-I in human PBMC [i5].
When whole blood was circulated in an in vitro dialysis circuit,
PBMC were stimulated to produce IL-i after addition of LPS to
the dialysate [16]. We reported previously that during in vitro
HD, LPS-like activity appears to penetrate the intact dialyzer
membrane from the dialysate into the blood compartment when
plasma is present on the blood side 117].
Another possible trigger for IL-I and TNFa induction during
HD is the direct contact between blood leucocytes and the
dialysis membrane. In the absence of LPS or complement,
cuprammonium (Cup) fragments [12, 18] as well as polyacry-
lonitrile [19] were able to induce IL-I activity in PBMC.
Adherence of cells to the dialysis membrane could activate
monocytes after which exposure to small amounts of microbial
products diffusing through the membrane may stimulate IL-I
synthesis and release. PBMC from patients on chronic HD
contain more intracellular IL-I than control subjects [20].
The third mechanism for monokine induction during HD is
likely mediated by complement factors. Several complement
components are generated during HD in vivo [2 1—23] and
purified natural C5a or C3a have been reported to stimulate IL-i
and TNFs production from PBMC in vitro [24—26].
However, most of the studies investigating induction of IL-i
during HD were based on biological assays that are also capable
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of responding to other cytokines such as IL-2, IL-4, IL-6 and
IL-7. Therefore, in the present study we employed specific
radioimmunoassays (RIA) for detection of IL-113 and TNFa.
More specifically, we investigated the transcription of these
monokines during in vitro HD of whole human blood using
cDNA probes. Since PBMC are highly sensitive to LPS, it has
been difficult to distinguish between direct effects of HD such as
adherence of cells to the membrane and the effects of LPS
contaminating the culture medium. To surmount these prob-
lems, we employed ultrafiltration to remove IL-i- and TNFa-
inducing levels of LPS [271. We employed two dialyzer mem-
branes known to differ in their complement stimulating
properties, as well as recombinant C5a,
Methods
In vitro HD circuit
A closed ioop in vitro HD system was used as described
previously [17]. Hollow fiber dialyzers with two different mem-
branes were studied. Cuprammonium dialyzers (TAF 10, 1.0
m2) were purchased from Terumo Corp. (Tokyo, Japan).
Polysulfone dialyzers (Hemoflow F40, 0.65 m2) were provided
by Fresenius AG (Bad Homburg, FRG). Pyrogen-free standard
blood tubing sets (Cobe Lab, Lakewood, Colorado, USA) were
aseptically attached and both the blood compartment (BC) as
well as the dialysate compartment (DC) were rinsed with 2 liters
of pyrogen-free saline. The volumes of the BC and DC including
the tubing were approximately 180 ml and 220 ml, respectively.
An acetate containing dialysate (40 mmol/liter) was prepared by
diluting a standard HD concentrate (Renalyte Cobe Lab.,
Lakewood, Colorado, USA) 1:35 in water. Both concentrate
and water were subjected to ultrafiltration [27]. Following the
rinsing procedure, the saline in the DC was replaced by acetate
dialysate and recirculated at a constant flow rate of QD = 250
mI/mm. LPS measurements using a qualitative Limulus Ame-
bocyte Lysate Test (Associates of Cape Code, Woods Hole,
Massachusetts, USA) with a sensitivity of 25 pg/mI did not
detect LPS in dialysate samples. Approximately 80 ml of
freshly drawn, heparinized (10 U/ml) blood from normal human
donors was filled into the BC replacing an equal volume of
saline and was circulated at a flow rate of QB = 200 ml/min. The
blood and the dialysate were circulated in a countercurrent
manner for two hours. The dialyzer was kept in a water bath at
37°C. Fluid shifts due to ultrafiltration, especially with the
highly permeable membrane, were monitored by weighing the
fluid reservoir continuously and corrected by changes in flow
rates.
The donors were bled three times on two consecutive days.
The first time blood was taken for separation of fresh PBMC
(Pre-HD) and for two hours circulation through one of the
dialyzers. The second time and third time blood was circulated
using the other type of dialyzer or blood tubing alone without
dialyzer. The order of these experiments was random.
Preparation of PBMC
PBMC were separated before and after two hours of HD by
centrifugation through Ficoll/Hypaque (Ficoll Type 400, Sigma;
Hypaque-M, 90%, Winthrop Breon Lab., New York, New
York, USA), prepared with ultrafiltered water. PBMC were
washed twice with normal saline and resuspended in RPM! 1640
culture medium (Whittaker M.A., Walkersville, Maryland,
USA), supplemented with 2 m L-glutamine, 100 U/ml penicil-
lin and 100 /.Lg/ml streptomycin. The RPMI was ultrafiltered
(F40) in order to remove microbial products [27]. PBMC were
counted using a Coulter counter (Coulter Electronics, Hialeah,
Florida, USA), were resuspended at 5 x 106 cells/mI with 2%
heat-inactivated human AB serum and 0.5 ml added to wells of
a 24-well tissue culture plate (Falcon 3047). An equal volume of
RPM! alone or RPM! containing LPS (10 ng/ml, LPS E. coli
055:B5, Sigma, St. Louis, Missouri, USA) was added and
incubated with the cells at 37°C in a humidified atmosphere
containing 5% CO2. Cytokine production was determined after
4 and 24 hours. Differential cell counts were assessed following
cytocentrifugation and staining with Duff-Quick (American Sci-
entific, McGaw Park, Illinois, USA). Monocytes were identified
by staining for a-naphthyl acetate esterase (Sigma); viability
was determined by trypan blue exclusion. Differential counts
were performed in a blinded fashion.
In some experiments, PBMC were incubated in 50 ml Falcon
polypropylene tubes (Becton and Dickinson, Lincoln Park,
New Jersey, USA). After an incubation period with different
concentrations of recombinant human C5a (Sigma) in the pres-
ence of 0.5 sg/ml indomethacin (Sigma), cells were lysed in
guanidine isothiocyanate for isolation of RNA. For culture, I ml
of cell suspension was transferred to a 24-well tissue culture
plate (Falcon 3047), further incubated for a total incubation
period of 24 hours and then subjected to RIA.
Assays for IL-i 13, TNFa, C5a(desArg) and iC3b
Total cytokine synthesis (cell-associated and secreted) was
obtained after three freeze-thaw cycles which was shown
previously to be optimal for determination of IL-1/3 [28].
Unstimulated samples were measured undiluted. Stimulated
samples were assayed in duplicates at two different dilutions in
order to calculate the concentration at a near 50% binding. The
sensitivity of the RIA for IL-1f3 was 80 pg/ml [29] and for TNFa
it was 40 pg/ml [301. In stimulated samples, cytokine concen-
trations were calculated as pg per 106 PBMC with the exception
of those depicted in Figures 7 and 8, and were expressed as
percent of cytokine production by freshly separated PBMC. To
assay IL-i bioactivity, the cloned murine helper T cell line
D1OS was employed as described [19]. Samples were assayed at
four different dilutions. Results were expressed as Stimulation
Index (SI). The background proliferation of D1OS cells without
stimuli was defined as SI = 1.0.
For determination of CSa(desArg) and iC3b, blood was
collected from the dialysis circuit in EDTA (20 mM), the plasma
obtained by centrifugation and stored at —70°C. iC3b was
measured by ELISA (Cytotech, San Diego, California, USA),
the sensitivity of the assay was 0.15 jsg/ml. C5a(desArg) was
determined by RIA (Amersham) that detects both C5a and C5a
desArg.
Preparation of polymorphonuclear cells (PMN)
PMN were separated from the cell pellet after separation of
PBMC by Ficoll/Hypaque. The cell pellet containing red cells
and PMN was diluted 1:3 with saline and an equal volume of 3%
dextran (Biorad, Richmond, California) was added. After sed-
imentation at room temperature for 45 minutes, the upper phase
containing the PMN was obtained and the cells were washed
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twice with saline. Red cells were lysed by hypotonic lysis in
0.2% saline for five minutes and isotonicity was reconstituted
by adding 1.6% saline. Differential counts revealed >96%
purity. PMN were resuspended at 5 x 106/ml in RPMI contain-
ing 2% human AB serum and incubated as described for PBMC.
RNA isolation and northern blot analysis
Before and after HD, PBMC were analyzed immediately after
Ficoll-Hypaque separation from whole blood. The interphase
layer was removed, added to 50 ml polypropylene tubes,
centrifuged at 500 x g for five minutes and cells were lysed in 4
M guanidine isothiocyanate [31]. Total cellular RNA was ob-
tained by centrifugation through 5.7 M cesium chloride in 0.1 M
EDTA. Equal amounts of RNA (20 p.gllane unless otherwise
indicated) were subjected to gel electrophoresis using 1.2%
agarose (IBI Inc., New Haven, Connecticut, USA) gels con-
taining 6.6% formaldehyde (Sigma) as a denaturing agent [32].
The RNA was visualized by staining with ethidium bromide
(Sigma) added to the loading buffer. Staining did not interfere
with the subsequent transfer. The RNA was transferred to
nylon membranes (Hybond-N, Amersham, Arlington Heights,
Illinois) and fixed by short-wave UV radiation. Prehybridiza-
tion, hybridization and autoradiography were performed using
standard techniques [31]. The nylon membranes were first
hybridized with the TNFa cDNA, stripped and subsequently
hybridized with the IL- 1/3 probe. For quantitation of mRNA
content the relative density of the autoradiograph was deter-
mined with a LKB ultrascan XL laser densitometer. The
strength of the signals on the autoradiograph was compared to
LPS-induced monokine mRNA on the same blot. The IL-lf3
probe was a 1075 bp fragment of the full length cDNA clone of
the IL-l/3 precursor [33] subcloned in pGEM2. The TNF
probe was a 473 bp fragment of the full length cDNA [341. The
DNA was labeled with 32P-dCTP by use of a random primer
DNA labeling kit (Boehnnger Mannheim, Mannheim, FRG).
DNA probes with specific activities > l0 cpm/ig DNA were
routinely obtained.
Statistics
Cytokine production by different PBMC populations was
compared using the Wilcoxon signed rank sum test. Results are
expressed as mean SD.
Results
Effect ofHD on IL-I/3 and TNFa production
As shown in Figure 1, production of IL-lp could not be
detected by freshly separated PBMC during a 24-hour incuba-
tion period. PBMC separated after two hours in vitro HD also
did not produce any IL-l/3, except in one case where IL-1/3
could be detected just above the detection limit. For TNFa, we
observed background levels in unstimulated cells of about 100
to 200 pg/mI. The amount of TNFa produced did not increase
alter HD. Monokine production was also not increased whether
HD was performed using Cup or PS or when blood was
circulated in tubing without a dialyzer. HD did not impair
viability of PBMC as judged by trypan blue exclusion; more-
over, additional stimulation with LPS resulted in readily detect-
able production of IL-l/3 and TNFa (Fig. 1).
We also employed a highly sensitive bioassay (D1OS) for
detection of IL- 1 bioactivity. These cells proliferate in response
to about 0.1 pg/mI recombinant IL-l/3. We did detect IL-i
activity in unstimulated cells in the range of 0.5 to 1.0 pg/ml.
However, even measuring biological activity of IL- 1 with this
highly sensitive cell line, there was no increase alter HD (Fig.
2).
Effect ofHD on transcription of IL -1 j3 and TNFc
PBMC analyzed before HD did not contain mRNA for IL-1f3
or TNFa. After HD using Cup significant expression of IL-1f3
and TNFa mRNA was observed in each of the three donors
PBMC (Fig. 3). mRNA for IL-1f3 and TNFa was readily
detectable after Cup HD in each of the experiments. PS did not
induce any detectable mRNA for IL-l/3 and considerably less
for TNFa compared to Cup. No transcription of either mono-
kine was induced when blood was circulated without a dialyzer.
We observed similar results using PBMC from three additional
donors (data not shown).
The amount of mRNA induction during HD was quantitated
by laser densitometry and the mRNA levels after HD were
compared to the amount of mRNA induced by 5 ng/ml LPS in
the same donors' PBMC. Since we compared mRNA-content
after HD with Cup or PS using the same donor's blood to the
same positive control, this method gives a relative quantitation
of mRNA induction by Cup or PS. As shown in Figure 4, when
the LPS-induced IL-1f3-mRNA was set at 100%, Cup induced
27.3 6% and PS did not induce detectable transcription of
IL-lp. For TNFa, Cup induced 26.4 8% and PS 13.2 3%.
We compared the production of IL-i/3 and TNFa from
LPS-stimulated PBMC before and after HD. Monokine produc-
tion was determined at 4 and 24 hours after stimulation. In
freshly isolated PBMC, the absolute production of IL-113 in
ng/106 PBMC averaged 0.42 0.14 (4 hr) and 4.6 2.6 (24 hr);
TNFa production was 1.4 0.4 (4 hr) and 2.2 1.8 (24 hr).
PBMC separated after HD with Cup or PS produced signifi-
cantly more IL-i$ and TNFa after four hours compared to
freshly isolated PBMC (Fig. 5). In contrast, when blood was
circulated for two hours without dialyzer, this "priming" effect
was not observed. Cytokine production was still elevated in
post-HD PBMC at 24 hours after LPS stimulation, but only for
TNFa this difference reached statistical significance: IL-l/3;
post-Cup = 134 68%; post-PS = 111 39%; post-tubing =
102 30 (all NS); TNFa; post-Cup = 219 137% (P < 0.05);
post-PS = 182 76% (P < 0.05); post-tubing = 123 79%
(NS).
Effect of ED TA on monokine and mRNA expression
To evaluate the contribution of complement to the induction
of monokine transcription during HD, either heparin (10 U/mI)
or EDTA (20 mM) were used during in vitro HD with Cup. As
shown in Figure 6, addition of EDTA resulted in less but still
demonstrable induction of IL-1f3 and TNFa mRNA when
compared to the induction in heparinized blood.
In this experiment complement factors were measured during
HD. Plasma iC3b levels increased from <15 g/ml to 177 pg/ml
and C5a(desArg) from <5 ng/ml to 48 ng/ml after two hours HD
using heparinized blood. No increase of these complement
factors was found during HD using EDTA-anticoagulated
blood. In two additional experiments using Cup and heparinized
88 Schindler et a!: IL-i and TNF gene expression during hemodialysis
Effect of recombinant C5a on monokine transcription
As shown in Figure 7, incubation of PBMC in medium alone
resulted in appearance of IL-l/3 mRNA. Incubation with recom-
binant C5a increased IL-lp and TNFa mRNA in a dose-
dependent fashion with optimal concentration at 50 nglml.
IL-1f3 mRNA levels at 50 nglml were similar to those induced
by 5 nglml of LPS; however, IL-l$ protein was barely detect-
able in the same cell cultures after 24 hours of incubation. The
lack of IL-l/3 levels was not due to differences in the kinetics of
C5a- and LPS-induced monokine mRNA. Employing the more
sensitive D1OS bioassay, we found a small but not significant
increase in IL-l/3 production over background levels in recom-
binant C5a-stimulated cells (data not shown).
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Fig. 1. Spontaneous IL-I 13 and TNFa
production by PBMC before and after HD.
PBMC were separated from whole blood
before or after in vitro HD with Cup or PS or
after circulation of whole blood in tubing
without a dialyzer. IL-l/3 (A) and TNFa (B)
were determined after incubating PBMC for
24 hours in RPM! alone (circles) or with 5 ng/
ml of LPS (triangles). Results from 5 different
experiments; some of the symbols overlap
because of the logarithmic scale for monokine
levels. The horizontal lines denote the
detection limit of the RIA.
Characterization of cell preparations
After HD with Cup, the FicolllHypaque preparations of
PBMC showed between 35 and 63% contamination with PMN,
averaging 46% 4 (N = 6). In contrast, before HD or after HD
with PS or tubing alone, only 1 to 2% of cells were PMN. The
high numbers of PMN could influence the IL-1f3 and TNFa
production by PBMC. Therefore PMN and PBMC were sepa-
rated from the same donor, incubated at different ratios and
stimulated with LPS. There was a linear relationship between
the numbers of PBMC and the IL-l/3 and TNFa production
(Fig. 8).
We also assessed the number of monocytes before and after
HD employing nonspecific esterase staining. In two additional
experiments, there was no change in the percentage of esterase-
positive cells in the PBMC population after HD with Cup
compared to the matched control of freshly isolated PBMC
from the same individuals: before HD there were 16% and
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blood, plasma C5a levels increased to 102 and 166 ng/ml,
respectively.
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Fig. 3. Induction of IL-1f3 and TNFa mRNA during in vitro HD.
PBMC were separated from the whole blood before and after 2 hours
HD or circulation in tubing alone and analyzed immediately after
separation. RNA was extracted and 15 tg/lane subjected to northern
analysis. The blot was first hybridized to the cDNA for TNFa, stripped
and subsequently hybridized to the IL-l/3 probe. Exposure time was 24
hours for IL-1/3 and 2 days for TNFa. The left most lane shows mRNA
extracted from PBMC stimulated with LPS (5 ng/ml) for 2 hours. An
additional 3 donors were studied and yielded similar results (data not
shown).
17.6% esterase-positive cells; after HD 15% and 18.2%, respec-
tively.
Discussion
Our studies demonstrate that in the absence of LPS, circula-
tion of whole blood through Cup or PS dialyzers is not sufficient
to induce production of IL-l$ or TNFa by PBMC. In contrast,
transcription of mRNA for both monokines was observed after
in vitro HD with Cup but to a considerably lesser extent with
PS. There was also no increase in IL-l activity employing a
highly sensitive bioassay for IL-l. The lack of spontaneous
monokine production after HD was not due to decreased
viability of the cells. On the contrary, subsequent LPS stimu-
lation for four hours resulted in even greater production of
IL-1f3 and TNFa compared to freshly isolated cells. Accord-
Fig. 2. Spontaneous production of IL-i
bioactivily. The same PBMC lysates shown in
Figure 1 were assayed for IL-I activity on
D1OS cells. A stimulation index of 1.0 is
defined as the proliferation of D1OS cells
without any additions, The inset shows a
typical dose response of the bioassay, with a
stimulation index of 3 equivalent to 0.1 pg/mI
of recombinant IL-l/3. +LPS denotes PBMC
lysates stimulated with 5 ng/ml LPS. Lysates
from unstimulated cells were assayed at a 1:10
dilution and from LPS stimulated cells in a
1:100 dilution. Results are mean SD of 3
experiments.
ND [I.j NDj ND
+ LPS Pre-HD Post-Cup Post-PS Post-tubing
Fig. 4. Quantitation of mRNA induction during HD. Symbols are: (U)
IL-113 mRNA; () TNFa mRNA. The mRNA levels detected by
northern blot analysis shown in Figure 3 were quantitated by laser
densitometry and expressed as percent of the mRNA induced by LPS.
Results are mean SD of 3 experiments employing different donors.
ND, not detectable.
ingly, HD serves as a "priming" event for these cells. At 24
hours after LPS stimulation, the "priming" effect could still be
observed but was significant only for TNFa. The reason for this
"priming" effect remains unclear. It is possible that the mRNA
accumulated during HD is more rapidly translated into protein
after subsequent LPS stimulation. PBMC from patients dia-
lyzed with Cup contained more IL-i activity compared to
controls [20] and this could be evidence of in vivo "priming"
since in vitro conditions of these experiments could have
provided a source of LPS. However, induction of mRNA
cannot be the only reason since PBMC were primed also after
HD using PS. Alternatively, upregulation of the number of LPS
receptors on PBMC during HD could be another possible
mechanism. This would also explain why the priming effect was
best observed at four hours after LPS stimulation but to a lesser
extent at 24 hours, since upregulation of LPS receptors would
result in a faster response to LPS. Investigation of the expres-
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Fig. 6. Influence of ED TA on mRNA induction during HD. Blood was
anticoagulated with heparin (10 U/ml) or EDTA (20 mM) and in vitro
HD using Cup was performed. RNA was extracted from PBMC
immediately after HD and subjected to northern analysis. The blot was
hybridized as described in Figure 3 with cDNAs for TNFa and IL-lf3.
Exposure time was 2 days for both IL-1/3 and TNFa. The left most lane
shows mRNA extracted from PBMC of the same donor stimulated with
5 nglml LPS for 2 hours.
200 50 10 1
C5a,ng/m/
Fig. 7. Recombinant C5a induces transcription of IL-113 (0) and
TNFa (0). PBMC were incubated with different concentrations of
recombinant C5a in polypropylene tubes for 4 hours. Fifteen micro-
grams per lane of total RNA was subjected to northern analysis;
exposure time was 12 hours. +LPS denotes RNA from PBMC stimu-
lated with S ng/ml LPS for 4 hours. Shown are also the corresponding
protein levels for each cell culture after 24 hours of incubation. Results
are representative of 3 experiments using different donors.
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Fig. 8. Effect of PMN on IL-Ip (E) and TNFc production (0). PBMC
and PMN from the same donor were separated, mixed in different
proportions and incubated with LPS (100 nglml) for 24 hours. The final
cell concentration was 2.5 x 106 cells/ml in all cases. The amount of
monokine measured by RIA using PBMC alone was set at 100%. The
asterisks denote a significant difference to 100% PBMC using the
Wilcoxon signed rank sum test (* = P < 0.05). Results are mean 5D
of 4 experiments.
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Fig. 5. 'Priming' of PBMC by in vitro HD. PBMC separated before or
after HD were stimulated with LPS (5 ng/ml) and IL-l/3 and TNFa
determined after incubation for 4 hours. Monokine production is
expressed as percent of production by 106 PBMC separated before HD.
Results are mean SD of 6 experiments. Symbols are: () pre-HD; ()
post-Cup; (0) post-PS; () post-tubing. Asterisks denote a significant
difference to pre-HD levels using the Wilcoxon signed rank sum test
(*=p<0O5)
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sion of a recently described [35] 80 kD LPS binding protein
would clarify this issue.
The observation that PBMC express mRNA for IL-l/3 and
TNFa after HD without producing the corresponding protein
was not surprising. We recently reported [36] that adherence of
PBMC to glass or plastic in the absence of complement activa-
tion resulted in accumulation of mRNA for IL-lf3 and TNFa
without detectable translation into protein. In that study we
concluded that production of IL-i 13 is regulated not only at the
transcriptional but to a greater extent at the translational level.
In addition to adherence, a second stimulus such as LPS is
required to induce translation of IL- 1/3-mRNA. In a similar
fashion, the induction of mRNA for IL-lJ3 and TNFa during
HD may result at least in part from adherence of PBMC to the
dialyzer membrane, since it is known that leucocytes adhere to
dialyzer membranes [37]. Especially for TNFa, mRNA was
also induced by PS and to a barely detectable degree by tubing
r
300
200
— r — n -
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alone. Since the PS dialyzer had a smaller surface than the Cup
dialyzer, it seems reasonable that PS induced less TNFa
mRNA via adherence than Cup.
Marked increased levels of C5a(desArg) and iC3b were
documented during in vitro HD with Cup, confirming activation
of the complement cascade during HD with Cup in these
experiments. Studies demonstrate activation of the alternative
pathway of complement during HD with Cup both in vivo and
in vitro [21, 22, 38]. In contrast, PS membranes were shown not
to activate complement or to a much lower degree than Cup [39,
40]. C5b-9 complexes have been shown to be generated also
during cardiopulmonary bypass [411. The generation of comple-
ment factors is believed to be responsible for many of the
changes in PMN function during HD, including leukopenia
[42—441, increased chemiluminescence and oxidative metabo-
lism [45, 461 and granulocyte aggregation [39, 471. In view of
these studies, it is not surprising that after HD with Cup, the
FicolllHypaque preparations contained 30 to 60% PMN, indi-
cating that complement factors were indeed activated. After
internalization of the C5a-receptor complex, PMN become
rapidly stimulated. The effects of complement on PMN include
cell swelling and changes in cell density [48], thus explaining
their presence in the mononuclear cell fraction of Ficoll/Hy-
paque gradients.
Our results suggest that complement plays a major role in
inducing transcription of IL-I f3 and TNFa during HD since
preventing complement activation by EDTA reduced induction
of mRNA. Moreover, recombinant C5a was also able to acti-
vate transcription of IL-l/3 without inducing IL-1/3 synthesis.
These results are in contrast to previous studies demonstrating
induction of IL- 1 and TNFc by complement factors [24—26].
Although in those studies care had been taken to exclude
contamination with LPS, the preparations of natural comple-
ment could have been contaminated with other IL- 1-inducing
substances that cannot be blocked by polymyxin B. Since we
observed a synergistic effect of recombinant C5a and LPS on
IL-i production (data not shown) it is possible that C5a primes
PBMC to respond to IL-l-inducing substances which are not
stimulatory in the absence of CSa. Alternatively, the concen-
trations of complement components generated during HD may
have been insufficient to induce cytokine synthesis. The RIA
for C5a(desArg) detects both C5a and C5a desArg, and the
latter form is 10- to 100-fold less active in vitro than C5a.
However, the effect of recombinant C5a was observed at
concentrations that have been measured during HD with cellu-
losic membranes in vivo [49]. Since we detected similar levels
in our in vitro model our findings are relevant to the situation in
vivo. On the other hand, the finding that recombinant C5a did
not induce synthesis of IL-i is in agreement with a recent
study demonstrating that highly purified, LPS-free natural
complement factors do not stimulate adherent macrophages to
produce IL-i [50]. The present study suggests that neither
recombinant C5a nor the natural complement components
generated during in vitro HD are sufficient to induce synthesis
of IL-l/3 or TNFa in fresh PBMC. The failure of recombinant
C5a to induce IL-l/3 and TNFa was not due to the suppressive
effects of prostaglandins on translation since the experiments
were carried out in the presence of indomethacin. The recom-
binant C5a used in the present study is not glycosylated, and
glycosylation might be essential for induction of IL-i; however,
recombinant CSa displaces natural C5a from its receptor [511
and has biological activities such as chemotaxis and generation
of superoxide production from neutrophils similar to that of
natural C5a [52].
The high numbers of PMN if Ficoll/Hypaque preparations
after HD with Cup could influence IL-l/3 and TNFa production
by PBMC. It was previously reported that PMN are capable of
producing IL-i as well as substances inhibiting IL-i activity on
thymocytes [53, 54]. However, in the present study we ob-
served a linear relationship between the number of PBMC and
IL-ip and TNFa production (Fig. 8), regardless of the numbers
of PMN in the cell preparation. Thus, we can exclude that PMN
produce significant amounts of these monokines. Although
PMN secrete IL-i/3 inhibitors interfering with the bioassay, we
could not detect any interference with the RIA. Moreover,
PMN produce at least 100 times less IL-l than PBMC.
It is also unlikely that the contaminating PMN after in vitro
dialysis with Cup influenced the northern blot analysis. We
found that the average yield of RNA from PMN is 10 to 15
sgIi08 cells. Similar yields have been reported before [55]. In
contrast, the average yield from PBMC in the present study is
80 to 100 tg/l08 cells. Thus, even assuming that 50% of cells in
our FicolllHypaque preparations were PMN, only 10% of the
extracted total RNA would be of PMN origin.
Our results are in contrast to other studies demonstrating
induction of IL-i production after direct contact of PBMC to
stationary Cup membranes [12, 18, 19]. We employed constant
circulation in the present study which could lead to less cell
membrane interactions than stationary incubation. Further-
more, the use of whole blood allowed plasma constituents to
bind to the membranes as demonstrated for both Cup and PS
membranes [56—58]. These bound plasma proteins could mask
PBMC activating membrane components. Finally, production
of IL-i is highly sensitive to LPS concentrations of 10 to 20
pg/mi, and in the present study we employed ultrafiltration of all
water and tissue culture media to eliminate any effects of LPS.
We also used human AB serum whereas the use of S to 10%
fetal calf serum [12, 18] is sufficient source for LPS to result in
high background levels of IL-i. In over 100 experiments,
published from this laboratory, we were unable to detect IL-i
production (cell-associated or secreted) from PBMC cultured
for 24 hours in ultrafiltered RPMI [27, 28, 30].
Several triggers have been suggested to be responsible for
monokine induction during extracorporal circulation, including
LPS contaminating the dialysate, intrinsic properties of the
dialyzer membrane, complement activation, and presence of
acetate in the dialysate. We now report that in the absence of
LPS, the latter three factors are not sufficient to induce synthe-
sis of IL-i/3 or TNFa from PBMC during in vitro HD, regard-
less of the membrane used. Care must be taken when extrapo-
lating the observations in the present study to the situation in
vivo, because in HD patients, monokine production might be
influenced by additional factors such as uremia or the underly-
ing disease. Nevertheless, the present results suggest that to
prevent monokine induction during extracorporal circulation
eliminating microbial contamination of the dialysate seems
vital. However, differences were found between the Cup and
the PS membrane in the induction of mRNA for IL-l$ and
TNFa; the presence of mRNA could lead to increased mono-
kine synthesis when additional stimuli such as dialysate LPS,
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infections or even passage of microbial products through lung
or intestinal capillaries provide a second signal which leads to
translation of the accumulated mRNA.
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